Biogen Submits Plegridy BLA Zacks.com Biogen has another multiple sclerosis candidate, daclizumab, in development with AbbVie ( ABBV - Snapshot Report ) . Biogen is currently a Zacks Rank #3 (Hold) stock. Companies that look well-positioned include Anika Therapeutics Inc. ( ANIK - Snapshot ... |
